Cantor Fitzgerald Weighs in on Krystal Biotech FY2025 Earnings

Krystal Biotech, Inc. (NASDAQ:KRYS) – Equities researchers at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Krystal Biotech in a research report issued to clients and investors on Thursday, February 20th. Cantor Fitzgerald analyst J. Schimmer anticipates that the company will post earnings of $6.22 per share for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $215.00 target price on the stock. The consensus estimate for Krystal Biotech’s current full-year earnings is $6.14 per share.

Several other research analysts have also commented on KRYS. Citigroup boosted their price objective on shares of Krystal Biotech from $206.00 to $215.00 and gave the stock a “neutral” rating in a research note on Thursday. HC Wainwright reaffirmed a “buy” rating and issued a $221.00 price objective on shares of Krystal Biotech in a report on Wednesday, February 19th. Finally, Chardan Capital boosted their target price on shares of Krystal Biotech from $212.00 to $218.00 and gave the company a “buy” rating in a research note on Thursday. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $210.00.

Krystal Biotech Stock Performance

NASDAQ:KRYS opened at $187.86 on Monday. Krystal Biotech has a one year low of $107.50 and a one year high of $219.34. The firm has a market cap of $5.41 billion, a P/E ratio of 62.83 and a beta of 0.84. The firm has a 50-day simple moving average of $157.85 and a 200-day simple moving average of $175.26.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings results on Monday, February 24th. The company reported $1.52 EPS for the quarter, beating the consensus estimate of $1.29 by $0.23. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The business had revenue of $91.10 million during the quarter, compared to analyst estimates of $91.35 million. During the same quarter in the previous year, the business posted $0.30 EPS. The company’s quarterly revenue was up 116.4% compared to the same quarter last year.

Institutional Investors Weigh In On Krystal Biotech

A number of hedge funds have recently modified their holdings of the business. Wilmington Savings Fund Society FSB purchased a new stake in shares of Krystal Biotech in the third quarter valued at about $40,000. GF Fund Management CO. LTD. purchased a new position in shares of Krystal Biotech in the fourth quarter valued at approximately $95,000. Huntington National Bank lifted its stake in Krystal Biotech by 97.6% in the third quarter. Huntington National Bank now owns 573 shares of the company’s stock worth $104,000 after acquiring an additional 283 shares during the last quarter. Blue Trust Inc. lifted its stake in Krystal Biotech by 242.4% in the third quarter. Blue Trust Inc. now owns 582 shares of the company’s stock worth $107,000 after acquiring an additional 412 shares during the last quarter. Finally, Covestor Ltd lifted its stake in Krystal Biotech by 972.7% in the fourth quarter. Covestor Ltd now owns 708 shares of the company’s stock worth $111,000 after acquiring an additional 642 shares during the last quarter. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction dated Friday, December 13th. The shares were sold at an average price of $164.78, for a total value of $4,119,500.00. Following the completion of the sale, the insider now directly owns 1,475,882 shares in the company, valued at $243,195,835.96. This represents a 1.67 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 14.10% of the stock is currently owned by company insiders.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).